Granulomatous rhinitis secondary to feline leishmaniosis: report of an unusual presentation and therapeutic complications

Rodolfo Oliveira Leal\(^1,2\)\(\dagger\), Hugo Pereira\(^1,2\), Clara Cartaxeiro\(^1\), Esmeralda Delgado\(^1,2\)\(\ddagger\), Maria da Conceição Peleteiro\(^1\) and Isabel Pereira da Fonseca\(^1\)

Abstract

Case summary A 12-year-old male neutered domestic shorthair cat underwent rhinoscopy due to inspiratory dyspnoea and stertor. Rhinoscopy showed signs of chronic rhinitis and a multinodular nasopharyngeal mucosa. A marked infiltrate of macrophages that contained intracellular parasitic forms morphologically compatible with Leishmania amastigotes were observed on histopathological examination of nasal and nasopharyngeal biopsies. PCR from nasal tissue was positive for Leishmania infantum DNA, confirming the diagnosis of granulomatous rhinitis secondary to this parasite. Two eyelid nodules were identified 2 weeks later. Fine-needle aspiration revealed Leishmania amastigotes within macrophages and in the background. Allopurinol therapy was started, but 5 days later the cat developed dermatological signs compatible with a cutaneous adverse drug reaction. The drug was discontinued and meglumine antimoniate prescribed. Twenty-five days later, the cat presented with acute kidney injury and meglumine antimoniate was discontinued. Despite clinical improvement after fluid therapy, mild azotaemia persisted. The cat was subsequently treated with nucleotides and active hexose correlated compounds (N-AHCC). Four months later upper respiratory signs were exacerbated. A relapse of granulomatous rhinitis was suspected and miltefosine therapy started. Chronic kidney disease (CKD) worsened during miltefosine treatment, having improved under fluid therapy. Since then, the cat has been treated with N-AHCC and renal diet and at the time of writing shows stable CKD with no recurrence of respiratory signs.

Relevance and novel information This case describes Leishmania infantum as a cause of granulomatous rhinitis in a cat without cutaneous lesions, reporting the alternative use of N-AHCC and miltefosine when allopurinol seemed to have induced a cutaneous rash and there was acute kidney injury (AKI) after meglumine antimoniate therapy.

Keywords: Leishmaniosis; miltefosine; nucleoside-analogues/N-AHCC; Leishmania; granulomatous; rhinitis

Accepted: 15 October 2018

Case description

A 12-year-old male neutered domestic shorthair cat was referred in July 2017 to the Internal Medicine service of the Veterinary Teaching Hospital at the Faculty of Veterinary Medicine University of Lisbon for rhinoscopy due to progressive worsening of inspiratory effort with concurrent stertor and episodic sneezing of several weeks’ duration. The cat was indoor-only and was feline immunodeficiency virus (FIV)/feline leukaemia virus (FeLV) negative. The owner reported no history of a

---

\(\dagger\)CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal

\(\ddagger\)Veterinary School Hospital – Faculty of Veterinary Medicine, University of Lisbon, Lisbon, Portugal

Corresponding author: Rodolfo Oliveira Leal DVM, PhD, Dipl. ECVIM-CA (Internal-Medicine), CIISA – Centre for Interdisciplinary Research in Animal Health, Faculty of Veterinary Medicine, University of Lisbon, Av Universidade Técnica, 1300-477, Lisbon, Portugal

Email: rleal@fmv.ulisboa.pt

Creative Commons Non Commercial CC BY-NC: This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 License (http://www.creativecommons.org/licenses/by-nc/4.0/) which permits non-commercial use, reproduction and distribution of the work without further permission provided the original work is attributed as specified on the SAGE and Open Access pages (https://us.sagepub.com/en-us/nam/open-access-at-sage).
cough or nasal discharge. The animal had a normal appetite, without digestive upset or other signs of illness. Body condition score (BCS) was stable for several months (BCS 6/9). Past medical history included recurrent dermatological signs, namely episodic ventral alopecia and pruritic excoriations. Fungal and bacterial cultures were found negative in the past, leading to the suspicion of an allergic disease, ectoparasites or a behavioural condition. Dermatological flare-up episodes had been controlled during the past 5 years by topical corticosteroid treatment and regular spot-on administration of selamectin. A recent biochemical profile performed by the referring veterinarian only revealed a moderate hyperproteinaemia (total proteins 9 g/dl; reference interval 6–8.2 g/dl).

Physical examination was unremarkable apart from the stertor associated with inspiratory effort. Differential diagnoses included infectious rhinitis, immune-mediated/allergic rhinitis or mechanical obstruction (due to polyp or neoplasia). Oral and nasal swabs were obtained to detect Chlamydia species, feline calicivirus and feline herpesvirus infections by PCR. Rhinoscopy was performed under general anaesthesia (premedication with methadone 0.1 mg/kg IV, induction under propofol 4 mg/kg IV followed by volatile isofluorane maintenance), using a broncho-fibrescope (6001 Storz, working channel 2.3 mm) for retrograde vision and a rigid rhinoscope (Forward-Oblique Telescope 30° Storz) for anterograde inspection. Rhinoscopy showed a mildly hyperaemic nasal mucosa, without turbinate lysis in both nasal cavities. The nasopharynx was not obstructed, but the mucosa showed a multinodular appearance with a mean nodule size of 2–3 mm diameter (Figure 1). The soft palate was moderately thickened. Biopsies were performed from both nasal cavities and nasopharynx tissue, and were submitted to histopathological examination and fungal culture. The animal was discharged under prednisolone therapy owing to the clinical suspicion of chronic rhinitis (0.3 mg/kg for 10 days followed by 0.2 mg/kg for 10 days).

Molecular tests were negative, as was fungal culture. A marked infiltrate of macrophages that contained intracellular parasitic forms morphologically compatible with Leishmania infantum amastigotes (the agent of zoonotic visceral–cutaneous leishmaniosis) were seen at histopathological evaluation of nasal and nasopharyngeal biopsies (Figure 2). Prednisolone therapy was immediately tapered, and the cat was re-evaluated. Stertor was persistent and two small (2 mm diameter) eyelid nodules in the upper and lower palpebrae of the left eye were identified (Figure 3).

The cat was anaesthetised in order to complete the investigations. The anaesthetic protocol consisted of premedication with methadone (0.1 mg/kg IV), induction with propofol (2 mg/kg IV), followed by volatile isofluorane maintenance. Fine-needle aspiration (FNA) of palpebral nodules was performed for cytological evaluation and nasal biopsies were repeated for Leishmania PCR. A blood sample was also obtained for complete blood count.

Figure 1 Rhinoscopy photos showing a non-ulcerated and multinodular nasopharyngeal mucosa (on the left) and mild hyperaemic nasal mucosa (middle photo and on the right). Arrows are showing the nasopharyngeal nodules (mean diameter 2–3 mm)

Figure 2 Nasal mucosa biopsy. The lamina propria is packed with large numbers of macrophages filled with Leishmania species. Respiratory epithelium on the lower left (haematoxylin and eosin, × 400). Insert: magnification of the same macrophages with a clearer view of the Leishmania amastigotes (haematoxylin and eosin, × 1000)
(CBC), biochemical profile, serum protein electrophoresis, anti-FIV antibody detection (Viracheck FIV; Synbiotics), FeLV DNA and RNA molecular detection (blood real-time PCR), and anti-Leishmania (Qualitative Elisa [IDEXX] and Leishmania Spot IF [Biomerieux]). This last one was validated in previous inter-laboratory assays using 100 feline serum samples, including positive and negative sera from the biobank of Parasitology Lab (Faculty of Veterinary Medicine – University of Lisbon). The cut-off dilution is set as 1/40 and a fluorescently labelled anti-cat IgG conjugate (anti-cat IgG MegaCor; MegaCor Diagnostik) is used. Repeatability and reproducibility were also previously assessed (results not published). A urine sample was obtained for urinalysis and protein: creatinine ratio (UPC). Moreover, thoracic radiographs (left lateral, right lateral and dorsoventral views) and abdominal ultrasound examination were performed.

Splenomegaly was the only observed abnormality. Spleen FNA was suggested but declined by the owner. Leishmania amastigotes filled macrophages and were seen free in the background in FNA smears from eyelid nodules (Figure 4); anti-Leishmania antibodies were detected (Immunofluorescence assay [IFA] titre 320) and Leishmania DNA was identified by PCR from nasal biopsies. Diagnosis of granulomatous rhinitis and palpebral dermatitis caused by Leishmania infection was confirmed. Both FIV and FeLV co-infections were excluded. Hyperproteininaemia, hypergammaglobulinaemia and mild proteinuria (UPC 0.6) were the only clinicopathological abnormalities observed. Urine specific gravity was 1.035. Treatment was initiated with allopurinol 10 mg/kg (Zyloric; FaesFarma) q12h.

Five days after the onset of allopurinol, the cat was presented for focal ear, cervical and head alopecia, erythema, exfoliation and crusting (Figure 5). Owing to the short-term therapy, there was no evident improvement of respiratory signs under allopurinol. Fungal culture was negative and an imprint of lesions revealed hyper-segmented neutrophils and some keratinocytes. No Leishmania amastigotes were observed. A cutaneous adverse drug reaction (CADR) was strongly suspected. Allopurinol was stopped and 4 days later dermatological lesions spontaneously resolved.

In lieu of allopurinol, the cat was prescribed meglumine antimoniate (Glucantime 50 mg/kg SC q24h; Boehringer Ingelheim Animal Health), and both renal function and protein profile were monitored 10 and 25 days later (Table 1). A moderate improvement in respiratory signs was observed 1 week after the onset of this therapy.

On day 25, the cat was presented for lethargy and progressive anorexia. At physical examination only a unilateral blepharospasm in the left eye was observed. Ophthalmological examination revealed the presence of a conjunctival oedema, deposition of fibrin in the anterior chamber and decreased intraocular pressure. These findings were consistent with anterior uveitis. Even if
other systemic causes could have contributed to the uveitis (eg, neoplasia or concurrent infections), the previous medical exploration did not reveal the presence of viral infections or significant changes on thoracic radiographs and abdominal ultrasound. Therefore, uveitis was assumed to be a consequence of leishmaniosis. Biochemical results confirmed the presence of a severe azotaemia (day 25; Table 1). CBC showed a neutrophilic non-specific leukocytosis (26.110/μl). Urine culture was negative. The cat was hospitalised for intravenous fluids (Ringer’s lactate with potassium chloride supplementation) and supportive care with maropitant (Cerenia 1 mg/kg q24h).

Table 1 | Timeline showing variations of creatinine, urea, urinary protein: creatinine ratio (UPC), urine specific gravity (USG), total proteins (TP), albumin (Alb) and the prescribed medical treatment

| Time points/medical treatment | Creatinine mg/dl (RI 0.8–1.6) | Urea mg/dl (RI 30–60) | UPC (<0.2) | USG g/dl (RI 6–8.2) | TP g/dl (RI 2.5–3.9) | Alb g/dl |
|-----------------------------|-----------------------------|---------------------|------------|-------------------|-------------------|--------|
| Diagnosis                   | 0.9                         | 62.5                | 0.6        | 1.035             | 9                 | 1.5    |
| – Started on allopurinol 10 mg/kg PO q12h |                |                     |            |                   |                   |        |
| – Allopurinol stopped 5 days later owing to a suspicion of CADR |                |                     |            |                   |                   |        |
| Day 0                       | 1.2                         | 75.9                | 0.6        | 1.035             | 9.6               | 2.5    |
| – Started on meglumine antimoniate 50 mg/kg SC q24h |                |                     |            |                   |                   |        |
| Day 10                      | 1.2                         | 20                  | *          | 1.025             | 9.6               | 2.7    |
| – Meglumine antimoniate was continued |                |                     |            |                   |                   |        |
| Day 25                      | 6.5                         | 119                 | *          | 1.030             | 9.1               | 2.8    |
| – Meglumine antimoniate was discontinued |                |                     |            |                   |                   |        |
| – Hospitalisation for fluid therapy, supportive and ocular treatment |                |                     |            |                   |                   |        |
| Day 34                      | 0.9                         | 31.4                | *          | *                 | *                 | *      |
| – Hospital discharge |                |                     |            |                   |                   |        |
| Day 44                      | 1.8                         | 117.8               | 0.4        | 1.030             | 7.58              | 3.59   |
| – Started on N-AHCC ½ tablet PO q24h + benazepril 0.5 mg/kg PO q24h |                |                     |            |                   |                   |        |
| Day 123                     | 1.89                        | 93.4                | 0.3        | 1.030             | 8.8               | 3.0    |
| – N-AHCC + benazepril were continued |                |                     |            |                   |                   |        |
| Day 162                     | 1.9                         | 83                  | 0.3        | 1.028             | 8.8               | 2.9    |
| – Started on miltefosine 2 mg/kg PO q24h for 28 days; N-AHCC + benazepril were continued |                |                     |            |                   |                   |        |
| Day 180                     | 3.84                        | 141.9               | *          | *                 | 9.35              | 2.96   |
| – Hospitalisation for fluid therapy and supportive treatment. Miltefosine and N-AHCC were continued; benazepril was discontinued |                |                     |            |                   |                   |        |
| Day 188                     | 1.96                        | 103.8               | <0.2       | *                 | *                 | *      |
| – Hospital discharge |                |                     |            |                   |                   |        |
| Day 204                     | 2.33                        | 120.6               | <0.2       | 1.028             | *                 | *      |
| – N-AHCC, renal diet, SC regular fluid therapy, intermittent administration of maropitant |                |                     |            |                   |                   |        |
| Day 213                     | 3.28                        | 198.9               | *          | 1.025             | 8.19              | 3.1    |
| – Same medical therapy and diet |                |                     |            |                   |                   |        |
| Day 268                     | 3.67                        | 138.1               | *          | 1.028             | 8.57              | 3.16   |
| – Same medical therapy and diet |                |                     |            |                   |                   |        |
| Day 315                     | 3.31                        | 115                 | <0.2       | 1.025             | 8.2               | 3.14   |
| – Same medical therapy and diet |                |                     |            |                   |                   |        |

RI = reference interval; CADR = cutaneous adverse drug reaction; N-AHCC = nucleotides and active hexose correlated compounds

*refers to missing data at each time-point

Treatment of uveitis consisted of topical dexamethasone (q6h), flurbiprofen (q6h) and tropicamide (q12h) until progressive remission of ocular signs 2 weeks later. Meglumine antimoniate was discontinued. Appetite and azotaemia normalised, and the cat was discharged 9 days later (day 34; Table 1). A renal diet (Purina N/F mixed dry and canned) was started. The animal was evaluated 10 days later (day 44; Table 1) without any report of adverse events or changes on physical examination. Chronic kidney
Leal et al

stable antibody titres (IFA titre 160). It was non-hypertensive and had borderline proteinuria; it was non-hypertensive and had started (Impromune ½ tablet once daily; Bioiberica). The cat condition was stable with stage 2 IRIS CKD, borderline proteinuria; it was non-hypertensive and had stable antibody titres (IFA titre 160).

Six months after first examination (day 123; Table 1), the owner declined further investigations to confirm the recurrence of granulomatous rhinitis. Considering the previous CADRs to allopurinol and AKI, and probably secondary meglumine antimoniate, evidence of concurrent immunosuppression, particularly owing to a brief use of prednisolone, which may have resulted in mild immuno suppression. Additional tests that supported a diagnosis of leishmaniosis were serological (IFA and ELISA) and PCR from nasal tissue. Moreover, clinical response to therapy and consequent regression of clinical signs also strengthened this diagnosis. Concurrent causes for immunosuppression such as retroviral infections were investigated but found to be negative. As in the majority of cases of feline leishmaniosis, evidence of concurrent immunosuppression, other than the brief use of topical prednisolone during flare-up dermatological episodes, was not identified.1,3

Because there are no controlled studies about feline leishmaniosis treatment, allopurinol was prescribed in this cat as this compound has been anecdotally proven to be successful.1–3 However, the acute presentation of dermatological signs 5 days after onset of this therapy led to the suspension of allopurinol CADR. Adverse reactions to this drug have been described in humans under-taking allopurinol.12–14 But to our knowledge, it has not been previously reported in cats. This dermatological reaction is believed to be due to a specific T-cell response activated by oxypurinol, one of the metabolites of allopurinol.15 Despite the absence of histopathological analysis, this reaction was strongly suspected owing to the fact that it happened several days after the onset of therapy and dermatological signs resolved after stopping allopurinol therapy.

Consequently, the therapeutic strategy was modified and meglumine antimoniate was started. Meglumine antimoniate is known to be potentially nephrotoxic in dogs;16 however, information about its side effects is still scarce. In this cat, an AKI episode was observed after 17 days. As there was no azotaemia before the onset of meglumine antimoniate therapy, it is possible that this compound led to tubular renal injury, as has been described in dogs.16 However, it is also possible that CKD was present, but silent (IRIS stage 1), in this geriatric patient and azo-
taemia progressively worsened after therapy. Use of the symmetric dimethylarginine assay may have enhanced our assessment of renal function before the onset of meglumine antimoniate therapy. This was not performed as local constraints (unavailability of this parameter in that period and financial issues) were a limitation in this case. Meglumine antimoniate was discontinued and azotaemia improved after IV fluid therapy. Nonetheless, there was a persistent mild azotaemia. A diagnosis of CKD was concurrently established, and therapy was adapted according to IRIS recommendations.

Recently, N-AHCC have been considered an alternative maintenance therapy to allopurinol (following meglumine antimoniate in dogs) showing similar activity against Leishmania species. To our knowledge, this is the first published study detailing the use of N-AHCC in a cat. Treatment did not worsen clinical signs or result in adverse side effects. Indeed, the cat was stable for 120 days. A few weeks after medical stabilisation (120 days after the start of N-AHCC and 140 days after stopping meglumine antimoniate therapy), respiratory signs recurred. It is unclear whether this improvement and concurrent relapse was due to the temporary effect of meglumine antimoniate and prolonged N-AHCC therapy or, from another perspective, possible N-AHCC treatment failure. Further studies are needed to assess the truly efficacy of N-AHCC in feline patients. As medical exploration was declined, a relapse of granulomatous rhinitis secondary to leishmaniosis was assumed. This was further supported by the good clinical response and improvement of respiratory signs under miltefosine.

Miltefosine is a well-known drug, currently used in human and canine leishmaniosis. Information concerning its use in cats is particularly scarce. A recent study has described hyporexia and weight loss as the main adverse effects of miltefosine therapy (2 mg/kg PO q24h) in feline refractory sporotrichosis. To our knowledge, only one case of feline leishmaniosis treated with miltefosine has been reported in the literature. Recognising the risk of unexpected side effects, use of this leishmanicidal therapy was started off label, using the same dosage currently recommended for dogs. However, azotaemia worsened during treatment. In humans, miltefosine-induced nephrotoxicity has been described in 29% of patients. In dogs, administration of this compound does not seem to induce renal lesions. As literature on this subject is scarce, possible miltefosine-induced CKD is possible in this scenario. However, an acute-on-chronic azotaemia unrelated to miltefosine or eventually worsened by the transient vomiting cannot be excluded. Considering the pros and cons of stopping this compound and recognising that there were no other alternatives for leishmaniosis management, miltefosine therapy was continued but under IV fluids. Despite the fact that CKD progressively worsened, the cat, at the time of writing, is stable (10 months after diagnosis) under medical therapy and following IRIS recommendations.

Conclusions

This case reinforces the idea that granulomatous rhinitis secondary to leishmaniosis should be included in the differential diagnoses of obstructive chronic rhinitis in cats, particularly in endemic areas. This case also explores the difficulties of medical management of this disease in feline patients, describing the alternative use of miltefosine and N-AHCC in a cat, when allopurinol appeared to have induced a cutaneous rash and there was AKI after meglumine antimoniate therapy.

Acknowledgements

We would like to thank Professor Solange Gil, and the medical and nurse staff of the Veterinary Teaching Hospital – Faculty of Veterinary Medicine, University of Lisbon, for the care provided to this cat during hospitalisation and follow-up. We also thank Dr Ryane Englar for reviewing the manuscript and Lidia Gomes for the technical support.

Conflict of interest

The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding

The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding for this work was provided by Centre for Interdisciplinary Research in Animal Health (CIISA) through project UID/CVT/276/2013.

ORCID iD

Rodolfo Oliveira Leal [https://orcid.org/0000-0002-2463-4062]
Esmeralda Delgado [https://orcid.org/0000-0001-9383-1310]

References

1. Pennisi MG, Hartmann K, Lloret A, et al. Leishmaniosi in cats: ABCD guidelines on prevention and management. J Feline Med Surg 2013; 15: 638–642.
2. Pennisi MG, Venza M, Reale S, et al. Case report of leishmaniosis in four cats. Vet Res Commun 2004; 28: 363–366.
3. Pennisi M-G, Cardoso L, Baneth G, et al. LeishVet update and recommendations on feline leishmaniosis. Parasit Vectors 2015; 8: 302. DOI: 10.1186/s13071-015-0909-z.
4. Basso MA, Marques C, Santos M, et al. Successful treatment of feline leishmaniosis using a combination of allopurinol and N-methyl-glucamine antimoniate. JFMS Open Rep 2016; 2. DOI: 10.1177/2055116916630002.
5. Navarro JA, Sánchez J, Peñaflé-Verdú C, et al. Histopathological lesions in 15 cats with leishmaniosis. J Comp Pathol 2010; 143: 297–302.
6. Ibba F. Un caso de rinite cronica in corso di leishmaniosi felina. Proc 62nd Int SCIVAC Congr Rimini Soc Cult Ital Vet Anim Compagnia; 2009 May 29–31; Rimini, Italy: Zoomark International.
7 Pennisi MG and Persichetti MF. Feline leishmaniosis: is the cat a small dog? Vet Parasitol 2018; 251: 131–137.
8 Altuzarra R, Movilla R, Roura X, et al. Computed tomographic features of destructive granulomatous rhinitis with intracranial extension secondary to leishmaniasis in a cat. Vet Radiol Ultrasound Epub ahead of print 11 July 2018. DOI: 10.1111/vru.12666.
9 Maia C, Sousa C, Ramos C, et al. First case of feline leishmaniosis caused by Leishmania infantum genotype E in a cat with a concurrent nasal squamous cell carcinoma. JFMS Open Rep 2015; 1: 1. DOI: 10.1177/2055116915593969.
10 Leiva M, Lloret A, Peña T, et al. Therapy of ocular and visceral leishmaniasis in a cat. Vet Ophthalmol 2005; 8: 71–75.
11 Rüfenacht S, Sager H, Müller N, et al. Two cases of feline leishmaniosis in Switzerland. Vet Rec 2005; 156: 542–545.
12 Halevy S, Ghislain P-D, Mockenhaupt M, et al. Allopurinol is the most common cause of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe and Israel. J Am Acad Dermatol 2008; 58: 25–32.
13 Ranu H, Jiang J and Ming PS. A case series of allopurinol-induced toxic epidermal necrolysis. Indian J Dermatol 2011; 56: 74–76.
14 Atzori L, Pinna AL, Mantovani L, et al. Cutaneous adverse drug reactions to allopurinol: 10 year observational survey of the dermatology department – Cagliari University (Italy). J Eur Acad Dermatol Venereol 2012; 26: 1424–1430.
15 Yun J, Mattsson J, Schnyder K, et al. Allopurinol hypersensitivity is primarily mediated by dose-dependent oxypurinol-specific T cell response. Clin Exp Allergy 2013; 43: 1246–1255.
16 Bianciardi P, Brovida C, Valente M, et al. Administration of miltefosine and meglumine antimoniate in healthy dogs: clinicopathological evaluation of the impact on the kidneys. Toxicol Pathol 2009; 37: 770–775.
17 Segarra S, Miró G, Montoya A, et al. Randomized, allopurinol-controlled trial of the effects of dietary nucleotides and active hexose correlated compound in the treatment of canine leishmaniosis. Vet Parasitol 2017; 239: 50–56.
18 Sundar S and Olliaro PL. Miltefosine in the treatment of leishmaniasis: clinical evidence for informed clinical risk management. Ther Clin Risk Manag 2007; 3: 733–740.
19 Solano-Gallego L, Miró G, Koutinas A, et al. LeishVet guidelines for the practical management of canine leishmaniosis. Parasit Vectors 2011; 4: 86. DOI:10.1186/1756-3305-4-86.
20 Miró G, Oliva G, Cruz I, et al. Multicentric, controlled clinical study to evaluate effectiveness and safety of miltefosine and allopurinol for canine leishmaniosis. Vet Dermatol 2009; 20: 397–404.
21 Manna L, Vitale F, Reale S, et al. Study of efficacy of miltefosine and allopurinol in dogs with leishmaniosis. Vet J 1997 2009; 182: 441–445.
22 Manna L, Corso R, Galiero G, et al. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol. Parasit Vectors 2015; 8: 289.
23 Silva FDS, Cunha SC dos S, Baptista AR de S, et al. Miltefosine administration in cats with refractory sporotrichosis. Acta Sci Vet 2018; 46: 1571. DOI: 10.22456/1679-9216.83639.
24 Bardagi M, Lloret A, Dalmau A, et al. Feline Leishmaniosis: 15 cases. Vet Dermatol 2016; 27 Suppl 1: 112–113.